EZT-OVC8-1 Protocol.
Description
Cells to transfect:
Cell Line Name: OVCAR8, OVCAR-8, OVCAR.8
Cell Synonyms: NCI60, NCI-60, NCI/ADR-RES, OVCAR-8, OVCAR.8
Patient’s Age: 64
Patient’s Sex: F
Prior Treatment: Ctx/Adr/CsPt/CyPh
Tissue Type: Ovary
Histology: Carcinoma-ud; epithelium
p53 Status: 0
ECAD Methylation: 48
MDR Function: 7
Institution: National Cancer Institute
Contributor: Hamilton, TC
Reference: Semin. Oncol. 11(3):285-298, 1984
Comments: NCI/ADR-RES was originally described as a breast cancer cell line, but later was identified as the same of ovarian cancer cell line OVCAR8.
OVCAR8 is one of the cell lines of the NCI-60 panel which represents different cancer types and has been widely utilized for drug screening and molecular target identification.
Transfection reagent features:
- Broad spectrum for the transfection of large plasmid, mRNA, siRNA, and/or other type of nucleic acids, which is best for co-transfection of different type and/or size of nucleic acids.
- Specifically optimized to deliver nucleic acids into OVCAR8 cells
- Highest efficiency to ensure experimental success: transfection efficiency up to 90%;
- Extremely gentle to cells:®viability up to 95%
- Much less reagent needed for each transfection: 0.5 ml is able to transfect about 1000 wells of 24-well plate
- Deliver single or multiple plasmids
- Synthesized from 100% animal origin-free components, making it easy to validate the absence of zoonotic diseases, such as BSE or viruses, in research experiments or cells lines
- Active in serum-containing medium
- Suitable for Reverse Transfection
- Reproducible: due to highly controlled chemical synthesis of each of the ingredients, the reagent forms uniformly sized complex particles with nucleic acids. With optimized protocol, our reagent will ensure the reproducible highest transfection results.
- Developed and manufactured by EZ Biosystems
Data:
FIG. 1. High throughput test of transfection efficiency (determined as RLU/mg) on OVCAR8 cells after transfection of luciferase reporter gene by using our 172 proprietary transfection formulas and several most popular commercial transfection reagents. The yellow box showed the results of 4 commercial transfection reagents. The red lines marked our candidate formulas with the highest transfection efficiency for OVCAR8 cells. This test result was confirmed with repeat experiments. The one that showed the optimal balance of potent & low cytotoxicity among those candidate formulas after flow cytometry analysis on the percentage of 7AAD positive cells was later named as this OVCAR8 Cell Avalanche® Transfection Reagent.
FIG. 2. OVCAR8 cells were transfected with GFP vector (pEGFP-N3) by using OVCAR8 Cell Avalanche® Transfection Reagent. The cells were visualized by Nikon Eclipse Fluorescence microscope 24 hours post transfection.
For Other Cells
OVCAR8 (NCI/ADR-RES) Cell Avalanche® Transfection Reagent (human ovary carcinoma cell) can also be used on the following cells with high transfection efficiencies.
IGROV-1 Cell
OVCAR-3 Cell
OVCAR-4 Cell
OVCAR-5 Cell
SK-OV-3 Cell
CHO-K1 Cell
Vero Cell
293 Cell
293T/17 Cell
B16-F10 Cell
Recommended protocols for these cells will be provided with the reagent. The protocols usually provide satisfactory transfection efficiency with invisible cytotoxicity. However, optimization may be needed for certain type of cells. Optimizations may include: the amount of DNA and this transfection reagent; cell density; transfection reagent/DNA ratio, or incubation time for the mixture of transfection reagent/DNA etc. For best transfection result, we recommend using the respective cell type/cell line specific Avalanche transfection reagents. Those reagents have been optimized on both recipes and protocols, and have been proved to have the best transfection results for the respective cell lines or primary cells. You can easily find the respective Avalanche transfection reagents specific for your cells by using the filters of our product list.
Additional Information
| Weight | 0.5 lbs |
|---|---|
| Adherence Phenotype |
Adherent |
| Cell Type |
Epithelial Cell |
| Disease |
Cancer |
| Names starting from |
O |
| Primary/Cell Line |
Cell Line |
| Product Sizes |
0.5 ml, 1.5 ml |
| Species |
Human |
| Tissue Sources |
Ovary |
| Subcategories |
Cell Type/Cell Line Specific |
Documents
Protocols
MSDS
Citations or Feedback
- Wallbillich, J. J., Josyula, S., Saini, U., Zingarelli, R. A., Dorayappan, K. D., Riley, M. K., . . . Selvendiran, K. (2017). High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. PLoS One, 12(1), e0170318. doi:10.1371/journal.pone.0170318
